Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 36% One Year Share Price Jump

• If you are wondering whether Jazz Pharmaceuticals at around US$190 a share is priced attractively or already baking in a lot of expectations, you are in the right place.
• The stock has shown strong momentum recently, with returns of 9.9% over 7 days, 15.8% over 30 days, 10.0% year to date and 35.8% over the last year, on top of 33.4% and 18.0% over the past 3 and 5 years respectively.
• Recent news around Jazz Pharmaceuticals has focused on the company as a specialty pharma player and its position in the wider pharmaceuticals and biotech space. This gives investors more information to weigh alongside these share price moves. This backdrop helps frame the question of whether current expectations in the price are conservative or generous.
• On Simply Wall St’s 6 point valuation framework, Jazz Pharmaceuticals currently scores 5 out of 6. Next, we will walk through what that means across different valuation methods, before finishing with a way to look at valuation that goes beyond any single model.

Jazz Pharmaceuticals delivered 35.8% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Jazz Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting those back into present dollar terms.

For Jazz Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.25b. Analyst inputs and subsequent extrapolations by Simply Wall St project free cash flow of roughly $2.12b by 2030, with a series of yearly estimates in between that are also converted into today’s dollars.

Pulling all of those discounted cash flows together, the model arrives at an estimated intrinsic value of about $776.61 per share. Compared with a current share price around $190, the DCF output suggests the stock is 75.5% undervalued on this measure.

This is a single model and it relies on assumptions about future cash flows and discount rates. It points to a wide gap between price and estimated value right now.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Jazz Pharmaceuticals is undervalued by 75.5%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

JAZZ Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Jazz Pharmaceuticals.

Approach 2: Jazz Pharmaceuticals Price vs Sales

For companies that generate revenue but may not have steady earnings, the P/S ratio is often a practical way to think about what you are paying for each dollar of sales. It sidesteps the noise that can come from one off items in earnings, while still linking valuation to the business size.

In general, higher growth expectations and lower perceived risk tend to justify a higher normal or fair multiple. Slower expected growth or higher risk usually go with a lower one. For Jazz Pharmaceuticals, the preferred multiple is P/S. The stock currently trades on a P/S of 2.75x, compared with the Pharmaceuticals industry average of 4.17x and a peer average of 3.50x.

Simply Wall St’s Fair Ratio is a proprietary take on what Jazz Pharmaceuticals’ P/S might be given factors such as its earnings growth, industry, profit margin, market cap and risk profile. This makes it more tailored than a simple comparison with peers or the broad industry, because it adjusts for company specific characteristics instead of assuming all firms deserve the same multiple. Jazz Pharmaceuticals’ Fair Ratio is 7.77x, meaning the current 2.75x P/S is lower than this estimate.

Result: UNDERVALUED

NasdaqGS:JAZZ P/S Ratio as at Mar 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Jazz Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page. It lets you connect your own story about Jazz Pharmaceuticals to a set of revenue, earnings and margin forecasts, compare the fair value that follows from that story with the current share price to help you consider whether the stock looks closer to a buy or a sell, and then see that Narrative update automatically as new earnings or news arrive. For example, one investor might plug in a more cautious view and arrive at a fair value closer to the lower US$147 price target, while another uses more optimistic assumptions and lands nearer the higher US$263 fair value. Both investors are using the same framework but different perspectives.

For Jazz Pharmaceuticals, here are previews of two leading Jazz Pharmaceuticals Narratives to make comparison easier:

These are not buy or sell calls. They are two different ways of tying the same set of facts to different expectations for the future. Your job is to see which one feels closer to how you view the business today.

🐂 Jazz Pharmaceuticals Bull Case

Fair value in this bullish narrative: US$219.40 per share

Implied pricing gap: around 13.2% below this fair value at the last close of US$190.46

Revenue growth assumption: 7.85% a year

• Focuses on new therapies in oncology and neuroscience, with assets such as Ziihera, zanidatamab, Epidiolex and sleep medicines supporting a broader, more diversified portfolio.
• Assumes that ongoing R&D, acquisitions like Chimerix and international roll outs extend patent life, widen the product mix and improve longer term earnings consistency.
• Flags real risks around patent expiries, pricing pressure, competition and debt, but views these as manageable if new launches and pipeline progress track current analyst expectations.

🐻 Jazz Pharmaceuticals Bear Case

Fair value in this more cautious narrative: US$187.00 per share

Implied pricing gap: around 1.9% above this fair value at the last close of US$190.46

Revenue growth assumption: 5.00% a year

• Emphasises upcoming patent expiries, the arrival of oxybate generics and tighter global drug pricing as headwinds for revenue and margins in key sleep and rare disease products.
• Highlights reliance on acquisitions and oncology rollout to offset pressure in legacy franchises, with added concern around integration, higher leverage and execution risk if several projects stumble at once.
• Sees Ziihera and other pipeline assets as important, but views the share price as more fully reflecting that potential, leaving less room for disappointment if launches or adoption are slower than analysts currently factor in.

Taken together, these Narratives show how the same company can screen as undervalued on some assumptions and closer to fairly priced on others. The useful part for you is not which one is right, but which set of assumptions about growth, margins, competition and pricing you find more realistic for Jazz Pharmaceuticals today.

Curious how numbers become stories that shape markets? Explore Community Narratives

Do you think there’s more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!

NasdaqGS:JAZZ 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We’ve created the ultimate portfolio companion for stock investors, and it’s free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

No Byline Policy

Editorial Guidelines

Corrections Policy

Source